SCLX Similar Chart Price Prediction
The price of SCLX is predicted to go up 20.64%, based on the high correlation periods with QNST. The similarity of these two price pattern on the periods is 98.73%.
SCLX
QNST
Up: 20.64%Similarity: 98.73%
SCLX Revenue Forecast
SCLX EPS Forecast
SCLX FAQs
What is SCLX revenue forecast for next quarter？
SCLX Analyst's Forecast
James Molloy
Alliance Global Partners
Strong Buy
2024-10-16
Price Target
$14
Downside
0%
Alliance Global Partners analyst James Molloy initiated coverage of Scilex with a Buy rating and $14 price target. The revenue-generating company has three FDA approved non-opioid pain products on the market currently, but "the main reason to own" the stock is for the company's Phase 3 developmental candidate Semdexa, a non-opioid injectable corticosteroid gel formulation for lumbosacral radicular, or sciatica, pain, the analyst tells investors. If approved, Semdexa could become the standard of care for sciatica and could become "a legitimate blockbuster" $1B-plus annual sales product at peak, the analyst says.
